Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for Medivir in connection with public offer
Mandate

Vinge acts for Medivir in connection with public offer

April 13, 2011

Vinge acts for Medivir in connection with the public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm) has announced a public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm). Vinge acts for Medivir.

Vinge’s team is headed by capital markets and public M&A partner Erik Sjöman and includes, among others, Christian Lindhé, Emil Hedberg, Jakob Warren and Markus Larsson. Göran Nyström (public M&A), Kristian Hugmark and Hanna Danwall (competition law) and Mattias Schömer and Maria Doeser (tax) are also on the team.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

 HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

 Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

 Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026